Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65


Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.

Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA.

Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y.


Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N.

Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019.


Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase 1 trials?

Simmet V, Eberst L, Marabelle A, Cassier PA.

Ann Oncol. 2019 Aug 21. pii: mdz286. doi: 10.1093/annonc/mdz286. [Epub ahead of print]


Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.


Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, Soria JC, Chawla S, de Weger V, Wagner AJ, Siegel D, De Vos F, Rasmussen E, Henary HA.

Invest New Drugs. 2019 Jul 29. doi: 10.1007/s10637-019-00840-1. [Epub ahead of print]


Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.

Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q, Paindavoine S, Pérol D, Baudet C, Attignon V, Pissaloux D, Heudel P, You B, Leyronnas C, Collard O, Trédan O, Bonnin N, Long J, Jacquin JP, Cassier PA, Derbel O, Freyer G, Viari A, Blay JY, Ray-Coquard I.

Eur J Cancer. 2019 Sep;118:156-165. doi: 10.1016/j.ejca.2019.06.017. Epub 2019 Jul 24.


Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I.

Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.


Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord JP, Blay JY.

Ann Oncol. 2019 May 22. pii: mdz163. doi: 10.1093/annonc/mdz163. [Epub ahead of print]


Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Rüttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, de Visser KE.

Nat Cell Biol. 2019 Apr;21(4):511-521. doi: 10.1038/s41556-019-0298-1. Epub 2019 Mar 18.


Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P.

JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.


Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC.

Eur J Cancer. 2018 Sep;101:201-209. doi: 10.1016/j.ejca.2018.06.031. Epub 2018 Aug 1.


A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.

Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY.

BMC Cancer. 2018 Jun 8;18(1):646. doi: 10.1186/s12885-018-4544-x.


A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome.

Rochefort P, Italiano A, Laurence V, Penel N, Lardy-Cleaud A, Mir O, Chevreau C, Bertucci F, Bompas E, Chaigneau L, Levy D, Ryckewaert T, Dumont S, Meeus P, Ranchere D, Blay JY, Cassier PA.

Sci Rep. 2017 Dec 20;7(1):17917. doi: 10.1038/s41598-017-17733-z.


The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.


[DNA repair as a therapeutic target].

Eberst L, Brahmi M, Cassier PA.

Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11. Review. French.


Targeting apoptosis in acute myeloid leukaemia.

Cassier PA, Castets M, Belhabri A, Vey N.

Br J Cancer. 2017 Oct 10;117(8):1089-1098. doi: 10.1038/bjc.2017.281. Epub 2017 Aug 24. Review.


External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis.

Albertsmeier M, Rauch A, Roeder F, Hasenhütl S, Pratschke S, Kirschneck M, Gronchi A, Jebsen NL, Cassier PA, Sargos P, Belka C, Lindner LH, Werner J, Angele MK.

Ann Surg Oncol. 2018 Mar;25(3):754-767. doi: 10.1245/s10434-017-6081-2. Epub 2017 Sep 11.


Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.

Angevin E, Cassier PA, Italiano A, Gonçalves A, Gazzah A, Terret C, Toulmonde M, Gravis G, Varga A, Parlavecchio C, Paci A, Poinsignon V, Soria JC, Drubay D, Hollebecque A.

Eur J Cancer. 2017 Sep;83:194-202. doi: 10.1016/j.ejca.2017.06.036. Epub 2017 Jul 24.


Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's).

Bétrian S, Bergeron C, Blay JY, Bompas E, Cassier PA, Chevallier L, Fayette J, Girodet M, Guillemet C, Le Cesne A, Marec-Berard P, Ray-Coquard I, Chevreau C.

Clin Sarcoma Res. 2017 May 10;7:10. doi: 10.1186/s13569-017-0076-4. eCollection 2017.


Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J.

J Clin Oncol. 2017 Jan 10;35(2):157-165. Epub 2016 Nov 21. Erratum in: J Clin Oncol. 2017 Mar 10;35(8):926. J Clin Oncol. 2019 Feb 1;37(4):358.


A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI.

Clin Cancer Res. 2016 Dec 1;22(23):5696-5705. Epub 2016 Aug 19.


Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.

Brahmi M, Vinceneux A, Cassier PA.

Curr Treat Options Oncol. 2016 Feb;17(2):10. doi: 10.1007/s11864-015-0385-x. Review.


Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, Piperno-Neumann S, Italiano A, Chevreau C, Cupissol D, Bertucci F, Bay JO, Collard O, Saada-Bouzid E, Isambert N, Delcambre C, Clisant S, Le Cesne A, Blay JY, Penel N.

J Clin Oncol. 2015 Sep 1;33(25):2797-802. doi: 10.1200/JCO.2015.60.8505. Epub 2015 Jul 27.


CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.


Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.

Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24.


Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study.

Cassier PA, Kantor G, Bonvalot S, Lavergne E, Stoeckle E, Le Péchoux C, Meeus P, Sunyach MP, Vaz G, Coindre JM, Linassier C, Labib A, Delcambre C, Bay JO, Leyvraz S, Dubergé T, Lagrange JL, Duret A, Blay JY.

Ann Oncol. 2014 Sep;25(9):1854-60. doi: 10.1093/annonc/mdu202. Epub 2014 Jun 8.


Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.


The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I.

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20. No abstract available.


Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D.

Ann Oncol. 2014 Jun;25(6):1222-8. doi: 10.1093/annonc/mdu108. Epub 2014 Mar 7.


Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S.

J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1.


Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death.

Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C, Niederfellner G, Cassier PA, Bernet A, Mehlen P.

EMBO Mol Med. 2013 Dec;5(12):1821-34. doi: 10.1002/emmm.201302654. Epub 2013 Oct 8.


A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.

Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Bui-Nguyen B, Blay JY, Tresch-Bruneel E, Fournier C, Clisant S, Amela EY, Cassier PA, Molimard M, Penel N.

Br J Cancer. 2013 Nov 12;109(10):2574-8. doi: 10.1038/bjc.2013.648. Epub 2013 Oct 22.


Emerging therapies for soft-tissue sarcomas.

Levard A, Tassy L, Cassier PA.

Hematol Oncol Clin North Am. 2013 Oct;27(5):1063-78. doi: 10.1016/j.hoc.2013.07.011. Review.


A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group.

Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, Ray-Coquard I, Chabaud S, Penel N, Berge Y, Dômont J, Italiano A, Duffaud F, Cadore AC, Polivka V, Blay JY.

Br J Cancer. 2013 Aug 20;109(4):909-14. doi: 10.1038/bjc.2013.442. Epub 2013 Aug 6.


Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.

Levard A, Derbel O, Méeus P, Ranchère D, Ray-Coquard I, Blay JY, Cassier PA.

BMC Cancer. 2013 Mar 11;13:109. doi: 10.1186/1471-2407-13-109.


Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.

Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS.

PLoS One. 2012;7(11):e47020. doi: 10.1371/journal.pone.0047020. Epub 2012 Nov 7.


Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer.

Clin Cancer Res. 2012 Aug 15;18(16):4458-64. Epub 2012 Jun 20.


Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.

Garcia VM, Cassier PA, de Bono J.

Cancer Discov. 2011 Aug;1(3):207-12. doi: 10.1158/2159-8290.CD-11-0161.


Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.

Ploquin A, Olmos D, Ferté C, Cassier PA, Kramar A, Duhamel A, Penel N.

Crit Rev Oncol Hematol. 2012 Aug;83(2):242-8. doi: 10.1016/j.critrevonc.2011.11.008. Epub 2012 Jan 9. Review.


Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?

Blay JY, Cassier PA, Ray-Coquard I.

Eur J Cancer. 2011 Sep;47 Suppl 3:S385-8. doi: 10.1016/S0959-8049(11)70213-1. Review. No abstract available.


Gastrointestinal stromal tumors of the stomach and duodenum.

Cassier PA, Blay JY.

Curr Opin Gastroenterol. 2011 Oct;27(6):571-5. doi: 10.1097/MOG.0b013e32834bb7f0. Review.


Therapeutic pipeline for soft-tissue sarcoma.

Cassier PA, Labidi-Galy SI, Heudel P, Dutour A, Méeus P, Chelghoum M, Alberti L, Ray-Coquard I, Blay JY.

Expert Opin Pharmacother. 2011 Nov;12(16):2479-91. doi: 10.1517/14656566.2011.604633. Epub 2011 Sep 13. Review.


Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, van der Graaf WT, Italiano A, Seddon B, Dômont J, Bompas E, Wagner AJ, Blay JY.

Cancer. 2012 Mar 15;118(6):1649-55. doi: 10.1002/cncr.26409. Epub 2011 Aug 5.


Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.

Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Ménétrier-Caux C, Trédan O, Goddard-Léon S, Pin JJ, Mignotte H, Bathélémy-Dubois C, Caux C, Lebecque S, Blay JY.

BMC Cancer. 2011 May 30;11:213. doi: 10.1186/1471-2407-11-213.


Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.

Blesius A, Cassier PA, Bertucci F, Fayette J, Ray-Coquard I, Bui B, Adenis A, Rios M, Cupissol D, Pérol D, Blay JY, Le Cesne A.

BMC Cancer. 2011 Feb 15;11:72. doi: 10.1186/1471-2407-11-72.


New developments in treatment of ovarian carcinoma: focus on trabectedin.

Cassier PA, Duret A, Trédan O, Carrabin N, Méeus P, Treilleux I, Guastalla JP, Ray-Coquard I.

Cancer Manag Res. 2010 Oct 1;2:233-42. doi: 10.2147/CMR.S9459.


Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.

Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, Chayvialle JA, Lombard-Bohas C.

Clin Colorectal Cancer. 2010 Oct;9(4):248-54. doi: 10.3816/CCC.2010.n.037.


A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.

Cassier PA, Ducimetière F, Lurkin A, Ranchère-Vince D, Scoazec JY, Bringuier PP, Decouvelaere AV, Méeus P, Cellier D, Blay JY, Ray-Coquard I.

Br J Cancer. 2010 Jul 13;103(2):165-70. doi: 10.1038/sj.bjc.6605743. Epub 2010 Jun 29.


Imatinib mesylate for the treatment of gastrointestinal stromal tumor.

Cassier PA, Blay JY.

Expert Rev Anticancer Ther. 2010 May;10(5):623-34. doi: 10.1586/era.10.33. Review.


Supplemental Content

Loading ...
Support Center